Tel +49 (0)30 560 42240, Mon - Fri, 9am - 1pm

Research and studies

A new study published by the University of Connecticut in the latest issue of Current Pharmaceutical Design shows that daily use of the telomerase activator TA-65® provided protective effects against metabolic abnormalities associated with Metabolic Syndrome.
This latest study confirms the findings on the extension of the telomeres in a randomized, double-blind, placebo-controlled study in vivo (human) of TA-65® over a period of one year.
Overall, this study demonstrates that telomerase activators such as TAT2 can represent a new class of therapeutics that enhance immune function at a fundamental cellular level, complement existing drugs for the treatment of HIV / AIDS and a variety of age-related disorders with immune deficiency.

Pioneering scientific in vivo study published

Pioneering scientific in vivo study published:
The telomerase activator TA-65® extends short telomeres and improves the health span of adult / old mice without increasing the incidence of cancer.
Telomeres play an important role in maintaining chromosome integrity and stability, and shortening telomeres is involved in the initiation and progression of malignant diseases.
Telomere shortening and corresponding cellular senescence of the retinal pigment epithelium contribute to the changes in age-related macular degeneration.
A short average telomeric length is associated with low telomerase activity and certain degenerative diseases.
TA-65® for Skin is a topical cream developed as a novel product with the active ingredient TA-65®, a pure molecule extracted from the Chinese herb Astragalus.
Researchers from the Intermountain Heart Institute from Salt Lake City presented results of 3,500 patients with cardiovascular disease (heart attack and stroke) at the Cardiology Annual Scientific Session in San Francisco.

Rejuvenation Research (Research on Rejuvenation)

A purely natural telomerase activator, which is part of a health care program.
Randomized, double-blind, placebo-controlled study with 35 subjects over 16 weeks.
A randomized, double-blind, placebo-controlled study with thirty-five subjects over 16 weeks.